CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2013.
Revenues were $6.4 million during the quarter ended September 30, 2013 compared to $0.1 million for the quarter ended September 30, 2012 and include amounts allocated to research and development services from the Celgene collaboration.
Net cash provided by operating activities during the nine months ended September 30, 2013 was $48.9 million. bluebird bio held $216.8 million in cash and cash equivalents as of September 30, 2013.
Total operating expenses for the quarter ended September 30, 2013 were $12.5 million as compared to $5.1 million for the same period in 2012.
bluebird bio reported a net loss of $6.1 million, or $0.26 per share, for the quarter ended September 30, 2013, as compared to net income applicable to common stockholders of $0.6 million, or $1.14 per share, for the quarter ended September 30, 2012.
Recent Business Highlights:
-- In October bluebird bio announced the first patient was transplanted in the Starbeam (ALD-102) study for childhood cerebral adrenoleukodystrophy
-- In October bluebird bio joined the Russell 2000 Index
"bluebird continues to make solid progress on multiple fronts," stated Nick Leschly, chief bluebird. "In October, we announced that the first patient had been transplanted in the Starbeam study for CCALD, an important step in advancing bluebird’s lentiviral gene therapy platform. We look forward to announcing the first patient treated in our LentiGlobin studies for the treatment of beta-thalassemia in the months ahead.”
Calendar Year 2013 Anticipated Milestones:
-- Announce the first patient transplanted with LentiGlobin for beta thalassemia major
-- Attend the Deutsche Bank BioFest conference on December 2nd, 2013
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in France for the treatment of beta-thalassemia major and severe sickle cell disease. A second phase 1/2 study with LentiGlobin in the United States has been initiated for the treatment of beta-thalassemia major.
bluebird bio also has an early-stage chimeric antigen receptor-modified T cell (CAR-T) program for oncology in partnership with Celgene Corporation.
bluebird bio has operations in Cambridge, Massachusetts and Paris, France. For more information, please visit www.bluebirdbio.com.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of the Company’s clinical studies and the timing of data announcement. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that our collaboration with Celgene will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.
bluebird bio, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
|Three months ended||Nine months ended|
|September 30,||September 30,|
|Research and license fees||134||85||304||255|
|Research and development||8,706||3,501||21,237||10,713|
|General and administrative||3,836||1,608||9,441||4,302|
|Total operating expenses||12,542||5,109||30,678||15,015|
|Loss from operations||(6,157||)||(5,024||)||(16,832||)||(14,760||)|
|Other income (expense), net:|
|Foreign currency gains||33||4||11||18|
|Re-measurement of warrants||-||(22||)||(440||)||67|
|Other income (expense), net||44||(17||)||(408||)||88|
|Net (loss) income applicable to common stockholders - basic||$||(6,113||)||$||315||$||(17,240||)||$||111|
|Net (loss) income applicable to common stockholders - diluted||$||(6,113||)||$||632||$||(17,240||)||$||243|
|Net (loss) income per share applicable to common|
|Weighted-average number of common shares used|
|in computing net (loss) income per share applicable to|
bluebird bio, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
|September 30,||December 31,|
|Cash and cash equivalents||$||216,791||$||67,011|
|Prepaid expenses and other current assets||4,676||773|
|Total current assets||221,467||67,784|
|Property and equipment, net||5,392||1,288|
|Liabilities, convertible preferred stock, and stockholders' equity (deficit)|
|Accrued expenses and other current liabilities||5,006||2,115|
|Deferred revenue, current portion||25,340||340|
|Total current liabilities||31,490||4,628|
|Deferred rent, net of current portion||2,529||46|
|Deferred revenue, net of current portion||36,543||340|
|Convertible preferred stock||-||119,840|
|Total stockholders' equity (deficit)||157,700||(55,747||)|
|Total liabilities, convertible preferred stock and stockholders' equity (deficit)||$||228,262||$||69,322|